Business Wire

BEARINGPOINT

27.3.2024 12:00:31 CET | Business Wire | Press release

Share
BearingPoint Elects Stefan Penthin to Be the Next Managing Partner of the Global Firm

With, as planned, the final term of its current Managing Partner coming to an end, the partnership of the independent management and technology consultancy, BearingPoint, has elected Stefan Penthin to be its next Managing Partner, effective September 1, 2024. He will succeed Kiumars Hamidian, who successfully headed the business since his appointment in 2018, and did not stand for re-election after two terms in office as planned. The new Managing Partner was elected by the BearingPoint Partners in a collaborative process based on the principle of One Partner - One Vote.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327335930/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Stefan Penthin will be the next worldwide Managing Partner of BearingPoint. (Photo: Business Wire)

Stefan Penthin comments: “I am honored to be entrusted as the next Managing Partner of our firm and am fully committed to the long-term success of our clients and the partnership. We have extraordinary people and a strong portfolio driven by the spirit of innovation and entrepreneurship. We will go further with our mission, creating lasting outcomes for our clients, and enabling people to succeed.”

Stefan Penthin has been with BearingPoint for 23 years and became a Partner in 2012. He is a member of the firm’s global Management Committee and of the German Executive Committee. He is also the global leader for BearingPoint’s market segments as well as the global leader for Automotive & Industrial Manufacturing. Stefan brings more than 25 years of experience in business consulting to the table and has been leading large global consulting projects and business transformation programs with a focus on automotive and manufacturing industries. Stefan’s functional expertise is centered around supply chain management, operational excellence, as well as production and logistics optimization. His clients include major multinational corporations as well as specialized segment players across the globe.

Kiumars Hamidian comments: “Congratulations to Stefan Penthin! With him taking up the role as Managing Partner in September, I know that our business is in the safest possible hands. Stefan is a highly trusted leader and has been exceptionally successful in creating client value, he has excellent abilities, deep industry expertise, and an outstanding commitment to our values and principles. In his role as the global leader for our market segments, Stefan has made a significant contribution to the outstanding business success of our firm with revenues increasing to over EUR 1 billion. The transition process is well on schedule, and fully supported by the entire partnership of our firm.”

Kiumars Hamidian, Managing Partner at BearingPoint since 2018, guided BearingPoint successfully through the pandemic and to new heights. Under his leadership, revenues rose to more than EUR 1 billion and the number of employees increased to more than six thousand in 2023.

During Hamidian’s time in office, 13 acquisitions were delivered, a new subsidiary in India opened, and the US and Asia business expanded. In addition, the first joint venture (Arcwide) has been successfully established, and BearingPoint RegTech and BearingPoint Beyond (today flourishing as independent companies) have been successfully spun off. Moreover, BearingPoint established its purpose “Together, we are more than business,” and embraced a people-centric culture. Once the handover to Stefan Penthin is complete, Kiumars Hamidian will start his official early retirement phase in early 2025.

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provide IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com 
LinkedIn: www.linkedin.com/company/bearingpoint 
X: @BearingPoint

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240327335930/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye